Study to evaluate concordance of detecting EGFR (Epidermal Growth Factor Receptor) mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (Non-small cell lung cancer). - CONCORDANCE

Study identifier:D5161R00003

ClinicalTrials.gov identifier:NCT03562819

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR (Epidermal Growth Factor Receptor) mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (Non-small cell lung cancer).

Medical condition

NSCLC (Non-small cell lung cancer)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

268

Study type

Observational

Age

N/A

Date

Study Start Date: 16 Aug 2018
Primary Completion Date: 07 Jun 2019
Study Completion Date: 07 Jun 2019

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria